142044-78-8

Basic information

• Product Name: 1H-Pyrrole-2-carbonitrile, 1-[4-(bromomethyl)phenyl]-
• CAS NO: 142044-78-8
• Molecular Formula: C12H9BrN2
• Molecular Weight: 261.121
• Mol File: 142044-78-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-Pyrrole-2-carbonitrile, 1-[4-(bromomethyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrole-2-carbonitrile, 1-[4-(bromomethyl)phenyl]-(142044-78-8)
• EPA Substance Registry System: 1H-Pyrrole-2-carbonitrile, 1-[4-(bromomethyl)phenyl]-(142044-78-8)

Safety Data

• Hazardous Substances Data: 142044-78-8(Hazardous Substances Data)

Usage

Pyrrole derivative

A chemical compound derived from the pyrrole structure This indicates that the compound is based on the pyrrole structure, which is a five-membered aromatic ring with one nitrogen atom.

Carbonitrile group

A cyano group (CN) attached to the pyrrole ring This is a functional group present in the compound, consisting of a carbon atom triple-bonded to a nitrogen atom.

Substituted phenyl ring

A phenyl ring with a bromothiophene substitution This indicates that the compound has a phenyl ring attached to the pyrrole, with a bromothiophene group as a substituent.

Commonly used in organic synthesis, pharmaceuticals, and agrochemicals

The compound is widely used in the synthesis of other compounds, as well as in the production of drugs and pesticides.

Potential pharmacological activities

The compound has been studied for its potential antifungal and antibacterial properties This suggests that the compound may have potential therapeutic uses.

Useful building block for the synthesis of biologically active compounds

The presence of the bromothiophene substitution makes the compound a valuable intermediate for the synthesis of other biologically active compounds.

Upstream product

• 106-49-0 p-toluidine 
• 35524-48-2 1-(4-methylphenyl)pyrrole-2-carbonitrile 
• 827-60-1 1-(4-methylphenyl)-1H-pyrrole 
• 30186-38-0 1-(4-methylphenyl)-2-formyl-1H-pyrrole 

Downstream Products

• 144062-76-0 1-<4-(bromomethyl)phenyl>-3,5-dichloro-1H-pyrrole-2-carbonitrile 
• 144062-65-7 1-<4-<(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl>phenyl>-1H-pyrrole-2-carbonitrile 
• 167372-28-3 2-Cyano-1-((4-(N-methylamino)methyl)phenyl)pyrrole 
• 145355-20-0 1-[4-(3,5-Dibutyl-[1,2,4]triazol-1-ylmethyl)-phenyl]-4-nitro-1H-pyrrole-2-carbonitrile 
• 149323-93-3 methyl 2-butyl-1-[[4-[2-(1H-tetrazol-5-yl)-1-pyrrolyl]phenyl]methyl]benzimidazole-7-carboxylate 
• 149323-02-4 methyl 2-butyl-1-[[4-(2-carbonitrile-1H-pyrrol-1-yl)phenyl]methyl]-1H-benzimidazole-7-carboxylate 
• 942429-50-7 C₂₅H₂₄N₄O₂ 
• 942429-49-4 C₂₆H₂₆N₄O₂ 
• 942429-48-3 C₂₂H₁₈N₄O₂ 
• 942429-47-2 C₂₃H₂₀N₄O₂ 
• 942429-51-8 C₂₄H₂₃N₇O₂ 
• 942429-46-1 C₂₄H₂₂N₄O₂ 
• 942429-45-0 C₂₅H₂₄N₄O₅ 
• 942429-44-9 C₂₆H₂₆N₄O₅ 

Relevant articles and documents

FUSED HETEROCYCLIC COMPOUNDS, HAVING ANGIOTENSIN II ANTAGONISTIC ACTIVITY

Fused heterocyclic compounds of the formula (I): STR1 wherein R. sup.1 is an optionally substituted hydrocarbon residue which may be attached through a hetero atom; R 2 is a group capable of forming an anion or a group convertible thereinto; R 3 is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; X is a direct bond or a spacer having an atomic length of two or less between the R 3 group and the ring W group; W is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hereto atom; a,c and d are independently selected from the group consisting of one or two optionally substituted carbon atoms and one or two optionally substituted hetero atoms; b and e are independently selected from the group consisting of one optionally substituted carbon atom and one optionally substituted nitrogen atom wherein one of b or e must be nitrogen; the dotted line is a bond to form one double bond; n is an integer of 1 or 2 and when a, which is an optionally substituted carbon atom, is taken together with R 1, the following group: STR2 may form a ring group; provided that when STR3 is a benzimidazole, thieno[3,4-d] imidazole, or thieno[2,3-d] imidazole ring, at least one of the group: STR4 and R 3 is an optionally substituted heterocyclic residue; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.

ANGIOTENSIN II ANTAGONIZING HETEROCYCLIC DERIVATIVES

The invention relates to compounds of the formula STR1 wherein STR2 represents a condensed or uncondensed imidazolyl ring and the rest of the variables are as defined in the specification. They are angiotensin II antagonists useful for treating hypertension, etc..